COMBINATIONS OF MODALITIES FOR THE TREATMENT OF DIABETES
A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule and a Type 1 diabetes autoantigen. Pharmaceutical compositions are also provided herewith.
1 .- 19 . (canceled)
20 . A pharmaceutical composition comprising:
about 0.5 to about 10 mg of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) fusion protein,
about 250 mg to about 2000 mg of a preproinsulin, and
an oil-based carrier that is IFA or Montanide ISA pharmaceutically acceptable carrier.
21 . The pharmaceutical composition of claim 20 , wherein said CTLA4 fusion protein is abatacept.